---
document_datetime: 2023-09-21 17:42:33
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/biograstim-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: biograstim-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8527458
conversion_datetime: 2025-12-24 00:51:53.558474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Biograstim

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IA/0031/G            | This was an application for a group of variations. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Medicinal | 22/11/2013 product                  | n/a                                            |                                  |           |

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   |                    | longer authorised        |                                                                                                                                                                                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0029   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/10/2013 no      | SmPC and                 | Update of sections 4.4 and 4.8 of the SmPC to include a new adverse reaction, capillary leak syndrome, and a related warning following the same update for the originator. The PL is updated accordingly. |
| T/0028    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/08/2013 product | 09/10/2013               |                                                                                                                                                                                                           |
| R/0025    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/05/2013         | 25/07/2013 SmPC, Annex   |                                                                                                                                                                                                           |
| IA/0027/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation B.II.b.5.c - Change to in-process tests or limits Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/07/2013         | II, Labelling and PL n/a |                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | product - Deletion of a non-significant in-process test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| IA/0026   | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/04/2013 n/a                   |
| IB/0024/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits                                                                                                                                                                                                                                                                                                                                                                           | 18/01/2013 n/a authorised        |
| II/0022/G | This was an application for a group of variations. To introduce a new site for WCB manufacture. To introduce a new WCB lot and some modifications to the manufacturing process of the WCB (change in scale, harvesting time and freezing volume). B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol Medicinal | 15/11/2012 n/a product no longer |

<div style=\"page-break-after: always\"></div>

| IB/0023   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                         | 24/10/2012         | n/a           | SmPC, Annex II, Labelling and PL   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------------------|
| IB/0020/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation | 21/09/2012         | n/a           | authorised                         |
| IA/0021   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                            | 11/09/2012         | n/a no longer |                                    |
| II/0019   | Replacement of the peptide mapping method. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS Medicinal             | 19/07/2012 product | n/a           |                                    |
| IB/0017   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                       | 10/05/2012         | n/a           |                                    |

<div style=\"page-break-after: always\"></div>

| IA/0015/G   | This was an application for a group of variations. B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)   | 14/03/2012         | n/a                            |                       |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------|-----------------------|
| IAIN/0016   | A.1 - Administrative change - Change in the name MAH                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/03/2012         | n/a SmPC, authorised           | and/or address of the |
| IB/0014     | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                           | 08/12/2011         | Labelling and PL n/a no longer |                       |
| IA/0013/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction Medicinal                            | 25/10/2011 product | n/a                            |                       |
| II/0012/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/10/2011         | 20/10/2011                     |                       |

<div style=\"page-break-after: always\"></div>

|           | Introduction of additional sterile filtration steps in the manufacturing process for the active substance. In addition, new in-process tests and limits are introduced. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits   | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010   | Introduction of a new Pharmacovigilance System (TEVA DDPS Version 10), including a new Qualified person for Pharmacovigilance. Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement. C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH 23/06/2011 Medicinal product                                                                                                | 05/08/2011 Annex II The MAH has introduced a new pharmacovigilance system used by TEVA Pharmaceutical Industries Ltd., which will be applied for the product Biograstim. The detailed description of this pharmacovigilance system includes information pertaining to the qualified person responsible for pharmacovigilance, the global structure of the pharmacovigilance organisation, company procedures relating to pharmacovigilance activities, global safety databases, links with other organisations, training and the quality management system. The MAH has also taken the opportunity to update Annex II.B with the latest wording as per October 2010 CHMP procedural announcement. no longer |
| IB/0011/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test 20/07/2011                                                                                                                                                                                                                     | n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                    |               |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009/G | This was an application for a group of variations. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 21/02/2011         | n/a           | SmPC and PL | To implement changes requested in the PSUR 3 Assessment Report (dated 06 August 2010), as well as to bring the Product Information in line with the SmPC of the reference product (Neupogen). Minor linguistic amendments are introduced in the Package Leaflet for the following languages: CS, DA, ET, ES, FI, FR, HU, IT, NL, PL . In addition, the MAH amended the European Medicines Agency web address in section 10 of the SmPC. authorised |
| IB/0008   | new additional data are submitted by the MAH B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                             | 27/08/2010         | n/a no longer |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0005   | Addition of an alternative site for manufacture (formulation, filling) of drug product. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. Medicinal                                                                                                                                                                | 24/06/2010 product | 06/07/2010    |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0006   | To change a test procedure for the active substance B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for                                                                                                                                                                                                                                                                                           | 20/05/2010         | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | the AS or a starting material/intermediate                                                                                                                                                 |                    |                      |                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|----------------------------------|
| IB/0007 | To change a test procedure for the finished product B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 20/05/2010         | n/a                  |                                  |
| IA/0004 | B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                     | 05/03/2010         | n/a                  | PL authorised                    |
| II/0001 | Extension of the finished product shelf-life from 24 to 30 months. Change(s) to shelf-life or storage conditions                                                                           | 19/11/2009         | 23/12/2009 no longer | SmPC, Annex II, Labelling and PL |
| IA/0002 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                | 06/10/2009 product | 06/10/2009           | SmPC, Labelling and PL           |
| IA/0003 | IA_28_Change in any part of primary packaging material not in contact with finished product Medicinal                                                                                      | 06/10/2009         | 06/10/2009           | SmPC, Labelling and PL           |